factually
Index/Topics/Gantenerumab clinical trial

Gantenerumab clinical trial

Gantenerumab’s effects on amyloid levels and clinical decline

Fact-Checks

2 results
Feb 6, 2026

Which Alzheimer’s treatments are in phase 3 trials with potential 2026 readouts and who are the funders?

Several high‑profile Phase 3 Alzheimer’s trials could report results in 2026, including ’s anti‑amyloid , ’s EVOKE program, ’s pivotal study, the POLARIS‑AD trial of AR1001, and a phase 3 trial; fundi...

Jan 22, 2026

What Centiloid changes after anti‑amyloid therapy have been observed in trials, and how do they map to clinical benefit?

of anti‑amyloid monoclonal antibodies have repeatedly shown large Centiloid (CL) reductions—often taking mean group values from high baseline CL into ranges below the conventional positivity threshold...